Evidence map›Paper›PMID 27996099›Full record

ArticleThe Laryngoscope2017

Preliminary study of a novel transfection modality for in vivo siRNA delivery to vocal fold fibroblasts.

Iv Kraja, Renjie Bing, Nao Hiwatashi, Bernard Rousseau, Danielle Nalband, Kent Kirshenbaum, Ryan C Branski

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Laryngoscope, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Iv KrajaNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, U.S.A.
Renjie BingNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, U.S.A.
Nao HiwatashiNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, U.S.A.
Bernard RousseauBill Wilkerson Center for Otolaryngology and Communication Sciences, Department of Otolaryngology, Hearing and Speech Sciences, and Mechanical Engineering, Vanderbilt University Medical Center, Nashville, Tennessee, U.S.A.
Danielle Nalbandthe Department of Chemistry, New York University, New York, New York, U.S.A.
Kent Kirshenbaumthe Department of Chemistry, New York University, New York, New York, U.S.A.
Ryan C BranskiNYU Voice Center, Department of Otolaryngology-Head and Neck Surgery, New York University School of Medicine, New York, New York, U.S.A.
New York University · US

Funding

Optimal RNA-based therapeutics for vocal fold injury and fibrosisR01DC013277 · NIDCD · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BRANSKI, RYAN COMFORT · 2014 to 2018
$2.3M
NIDCD NIH HHS R01 DC013277
6 · The paper itself

Abstract

objectiveAn obstacle to clinical use of RNA-based gene suppression is instability and inefficiency of current delivery modalities. Nanoparticle delivery likely holds great promise, but the kinetics and transfection conditions must be optimized prior to in vivo utility. We investigated a RNA nanoparticle complex incorporating a lipitoid transfection reagent in comparison to a commercially available reagent. STUDY

designIn vitro.

methodsWe investigated which variables influence transfection efficiency of lipitoid oligomers and a commercially available reagent across species, in vitro. These variables included duration, dose, and number of administrations, as well as serum and media conditions. The target gene was Smad3, a signaling protein in the transforming growth factor-β cascade implicated in fibroplasia in the vocal folds and other tissues.

resultsThe two reagents suppressed Smad3 mRNA for up to 96 hours; lipitoid performed favorably and comparably. Both compounds yielded 60% to 80% mRNA knockdown in rat, rabbit, and human vocal fold fibroblasts (P < 0.05 relative to control). Dose and number of administrations played a significant role in gene suppression (P < 0.05). Suppression was more dose-sensitive with lipitoid. At a constant siRNA concentration, a 50% decrease in gene expression was observed in response to a five-fold increase in lipitoid concentration. Increased number of administrations enhanced gene suppression, ∼45% decrease between one and four administrations. Neither serum nor media type altered efficiency.

conclusionLipitoid effectively knocked down Smad3 expression across multiple transfection conditions. These preliminary data are encouraging, and lipitoid warrants further investigation with the goal of clinical utility. LEVEL OF EVIDENCE: NA. Laryngoscope, 127:E231-E237, 2017.

Indexed as

Gene SilencingNanotechnologyCell LineFibroblastsIn Vitro TechniquesRNA, Small InterferingSmad3 ProteinTransfectionTransforming Growth Factor betaVocal CordsRNA, Small InterferingSmad3 ProteinSMAD3 protein, humanTransforming Growth Factor betafibroblastlipitoidLipofectaminesiRNASmad3transfectionvocal foldvoice

Identifiers

PMID27996099
PMCPMC5476483
OpenAlexW2562325088

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.